Sears H F, Herlyn D, Steplewski Z, Koprowski H
J Biol Response Mod. 1984;3(2):138-50.
Twenty patients with metastasis of gastrointestinal malignancies were treated with an anti-colorectal cancer mouse monoclonal antibody 1083-17-1A of the IgG2a class between December 1980 and January 1983. With two exceptions, all patients received a single injection of monoclonal antibody in a dose range of 15-1,000 mg/patient. No untoward immediate or delayed reaction to the initial injection was observed in any of the patients. Mouse immunoglobulin circulated in the patients' blood for 2-50 days, depending on the dose of monoclonal antibody injected, and was detected in tumor tissue within 1 week of its administration. Eight of nine patients who received doses of 366-1,000 mg monoclonal antibody did not develop anti-mouse antibodies, while eight of nine who received less than 200 mg developed anti-mouse immunoglobulin antibody. Three of this heterogeneous group of patients have no detectable disease now--10, 13, and 22 months since immunotherapy.
1980年12月至1983年1月期间，20例胃肠道恶性肿瘤转移患者接受了IgG2a类抗结直肠癌小鼠单克隆抗体1083 - 17 - 1A治疗。除2例患者外，所有患者均接受了单次注射单克隆抗体，剂量范围为15 - 1000mg/患者。所有患者均未观察到对初次注射的即时或延迟不良反应。小鼠免疫球蛋白在患者血液中循环2 - 50天，这取决于注射的单克隆抗体剂量，并在给药后1周内在肿瘤组织中被检测到。接受366 - 1000mg单克隆抗体剂量的9例患者中有8例未产生抗小鼠抗体，而接受少于200mg的9例患者中有8例产生了抗小鼠免疫球蛋白抗体。在这组异质性患者中，有3例患者目前没有可检测到的疾病——自免疫治疗后分别为10、13和22个月。
